← Back to Search

Glucagon-like peptide-1 receptor agonist

Tirzepatide for Type 2 Diabetes (SURPASS-SWITCH Trial)

Phase 4
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have type 2 diabetes
No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 40
Awards & highlights

SURPASS-SWITCH Trial Summary

This trial is testing whether a different diabetes medication is more effective and has fewer side effects than increasing the dose of the current medication.

Who is the study for?
Adults with type 2 diabetes currently on a stable dose of dulaglutide can join this trial. They should have an HbA1c level between ≥7.0% and ≤9.5%, a BMI of ≥25 kg/m², and may be taking up to three other oral diabetes medications. Exclusions include severe heart failure, very low kidney function, history of pancreatitis or certain thyroid cancers, type 1 diabetes, serious eye problems due to diabetes, recent cardiovascular events or weight loss treatments.Check my eligibility
What is being tested?
The study is testing the effectiveness and safety of switching from weekly doses of dulaglutide to tirzepatide in comparison to increasing the dose of dulaglutide for adults with type 2 diabetes. Participants will either switch medication or receive higher doses.See study design
What are the potential side effects?
Possible side effects might include digestive issues like nausea or diarrhea, potential allergic reactions at injection sites, increased risk for pancreatitis and thyroid tumors based on similar drugs' profiles.

SURPASS-SWITCH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have type 2 diabetes.
Select...
I haven't taken, or have been on a stable dose of up to 3 diabetes medications for 3 months.
Select...
I have been taking a stable dose of dulaglutide weekly for at least 6 months.
Select...
I have type 2 diabetes.

SURPASS-SWITCH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 40
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 40 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Hemoglobin A1c (HbA1c)
Secondary outcome measures
Hypoglycemia
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Fasting Serum Glucose (FSG)
+9 more

Side effects data

From 2022 Phase 3 trial • 210 Patients • NCT05024032
40%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Gastroenteritis
11%
Vomiting
9%
Flatulence
9%
Abortion induced
7%
Amylase increased
7%
Lipase increased
7%
Abdominal pain upper
7%
Gingivitis
6%
Injection site reaction
6%
Menstruation irregular
6%
Abdominal pain
4%
Hyperuricaemia
4%
Hepatic function abnormal
3%
Vaginal infection
3%
Dizziness
3%
Uterine polyp
1%
Hiccups
1%
Supraventricular tachycardia
1%
Hand fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
10 mg Tirzepatide
15 mg Tirzepatide
Placebo

SURPASS-SWITCH Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TirzepatideExperimental Treatment1 Intervention
Participants will receive tirzepatide subcutaneously (SC)
Group II: DulaglutideActive Control1 Intervention
Participants will escalate their dulaglutide dose SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~7590

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,605 Previous Clinical Trials
3,199,420 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,338 Previous Clinical Trials
403,595 Total Patients Enrolled

Media Library

Tirzepatide (Glucagon-like peptide-1 receptor agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05564039 — Phase 4
Type 2 Diabetes Research Study Groups: Tirzepatide, Dulaglutide
Type 2 Diabetes Clinical Trial 2023: Tirzepatide Highlights & Side Effects. Trial Name: NCT05564039 — Phase 4
Tirzepatide (Glucagon-like peptide-1 receptor agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05564039 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many venues are actively conducting this experiment?

"Clinvest Research LLC in Springfield, Missouri, Metabolic Research Institute, Inc. in West Palm Beach, Florida and NorthShore University Health System in Skokie, Illinois are all sites observing this trial with an additional 10 locations also recruiting patients."

Answered by AI

Are there opportunities to become involved in this research project currently available?

"The clinical trial hosted on clinicaltrials.gov is not currently enrolling participants; the protocol was initially posted on December 8th 2022 and last edited November 23rd, 2022. However, there are 1,440 trials actively searching for candidates at this moment."

Answered by AI

Has the FDA sanctioned Tirzepatide for medicinal use?

"Thanks to the completion of a Phase 4 trial, Tirzepatide was deemed safe and given a score 3 out of 3."

Answered by AI

Who else is applying?

What state do they live in?
Florida
Illinois
Texas
What site did they apply to?
ALL Medical Research, LLC
Juno Research
Biopharma Informatic, LLC
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
2
0
~50 spots leftby Aug 2024